Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Biological: cixutumumab
Drug: temsirolimus
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2009-04-13

Last Posted Date: 2014-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00880282

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Childrens Hospital of Orange County, Orange, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 20 locations

Collection of Tissue Samples for Study of Multidrug Resistance

Completed

Conditions: Breast Carcinoma
Medullary Thyroid Carcinoma
Breast Cancer

First Posted Date: 2009-04-13

Last Posted Date: 2019-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 325

Registration Number: NCT00880503

Locations: 🇺🇸
Childrens Hospital, Pittsburgh, Pittsburgh, Pennsylvania, United States

Assessment of Screening Modalities for Gynecologic Cancers

Completed

Conditions: Endometrial Cancer
Controls Without Ovarian Cancer
Ovarian Cancer
Controls Without Endometrial Cancer

First Posted Date: 2009-04-13

Last Posted Date: 2020-11-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 118

Registration Number: NCT00879840

Locations: 🇺🇸
Mayo Clinic, Rochester, Rochester, Minnesota, United States

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Adult Solid Neoplasm
Pancreatic Acinar Cell Carcinoma
Pancreatic Ductal Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions: Other: Diagnostic Laboratory Biomarker Analysis
Drug: Erlotinib Hydrochloride
Drug: Gemcitabine Hydrochloride
Drug: Vismodegib

First Posted Date: 2009-04-08

Last Posted Date: 2025-03-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00878163

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Orlando Health Cancer Institute, Orlando, Florida, United States

and more 1 locations

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: B-cell Childhood Acute Lymphoblastic Leukemia
Recurrent Adult Lymphoblastic Lymphoma
T-cell Adult Acute Lymphoblastic Leukemia
T-cell Childhood Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Lymphoblastic Lymphoma

Interventions: Drug: L-asparaginase
Drug: doxorubicin hydrochloride
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate
Drug: cytarabine
Drug: prednisone
Drug: bortezomib
Drug: pegaspargase
Drug: methotrexate
Drug: etoposide phosphate
Drug: cyclophosphamide
Biological: filgrastim
Drug: leucovorin calcium
Other: laboratory biomarker analysis
Drug: High Dose MTX

First Posted Date: 2009-04-01

Last Posted Date: 2017-01-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 148

Registration Number: NCT00873093

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 168 locations

Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System

Phase 1

Completed

Conditions: Medulloblastoma
Pineoblastoma
Supratentorial Embryonal Tumor, Not Otherwise Specified

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide Phosphate
Drug: Isotretinoin
Other: Laboratory Biomarker Analysis
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Thiotepa
Drug: Vincristine Sulfate
Drug: Vorinostat

First Posted Date: 2009-03-23

Last Posted Date: 2022-01-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00867178

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 12 locations

Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

Active, not recruiting

Conditions: Anal Carcinoma
Cervical Carcinoma
Human Papillomavirus Infection
Human Papillomavirus-Related Cervical Carcinoma
Oral Cavity Carcinoma

First Posted Date: 2009-03-23

Last Posted Date: 2025-02-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8670

Registration Number: NCT00867464

Locations: 🇨🇷
Agencia Costarricense de Investigaciones Biomédicas (ACIB), Liberia, Guanacaste, Costa Rica

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Phase 2

Completed

Conditions: Stage III Skin Melanoma
Recurrent Melanoma
Stage IV Skin Melanoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Selumetinib

First Posted Date: 2009-03-20

Last Posted Date: 2015-08-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 167

Registration Number: NCT00866177

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Pazopanib Hydrochloride
Other: Pharmacological Study

First Posted Date: 2009-03-16

Last Posted Date: 2018-10-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT00861913

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 1 locations

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

Phase 1

Completed

Conditions: Diabetes
Fatty Liver
Obesity
Healthy Volunteers

Interventions: Drug: Alpha tocopherol
Other: Vitamin E
Other: Vitamin C

First Posted Date: 2009-03-16

Last Posted Date: 2025-06-29

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 50

Registration Number: NCT00862433

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy